Literature DB >> 23446424

Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Orsalia Alexopoulou1, Marie Bex, Peter Kamenicky, Augustine Bessomo Mvoula, Philippe Chanson, Dominique Maiter.   

Abstract

Acromegaly is frequently associated with alterations of glucose metabolism but factors predisposing these patients to exhibit impaired glucose tolerance or overt diabetes at diagnosis are poorly understood. This study included 148 patients with newly diagnosed acromegaly (80 men; mean age: 45 ± 20 year). All patients underwent an oral glucose tolerance test (OGTT), unless already treated for diabetes. Insulin sensitivity (S) and β-cell function (B) were also evaluated by homeostasis model assessment (HOMA). Normal glucose tolerance (NGT) was observed in 67 patients (46 %), impaired fasting glycaemia (IFG) or glucose tolerance (IGT) were found in 39 (26 %), and diabetes mellitus (DM) in 42 (28 %). NGT patients were 10 years younger than patients with abnormal glucose metabolism (p < 0.001) and diabetic patients had a higher BMI (p < 0.05). While HOMA-S was similar, HOMA-B was reduced in the IFG/IGT group (p < 0.05) and further in the DM group (p < 0.001). IGF-I z-score was higher in IFG/IGT (5.2 ± 1.4) and DM patients (5.4 ± 1.3) than in NGT patients (4.4 ± 1.3; p < 0.05), but fasting and post-OGTT GH levels were not different between groups. In multivariate analyses, family history of diabetes and IGF-I were associated with hyperglycaemia, BMI and IGF-I predicted insulin resistance, and age was inversely correlated with β-cell function. Impaired glucose metabolism is present in more than 50 % of patients at diagnosis of acromegaly, and is associated with an older age, a higher BMI, a family history of diabetes and a higher IGF-I z-score, but not with fasting or post-OGTT GH levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23446424     DOI: 10.1007/s11102-013-0471-7

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  37 in total

1.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

2.  Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.

Authors:  S Kasayama; M Otsuki; M Takagi; H Saito; S Sumitani; H Kouhara; M Koga; Y Saitoh; T Ohnishi; N Arita
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

3.  Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity.

Authors:  S Yakar; J L Liu; A M Fernandez; Y Wu; A V Schally; J Frystyk; S D Chernausek; W Mejia; D Le Roith
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

Review 4.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

5.  Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study.

Authors:  Georg Brabant; Alexander von zur Mühlen; Christian Wüster; Michael B Ranke; Jürgen Kratzsch; Wieland Kiess; Jean-Marie Ketelslegers; Lars Wilhelmsen; Lena Hulthén; Bernhard Saller; Anders Mattsson; Jürgen Wilde; Rudolf Schemer; Peter Kann
Journal:  Horm Res       Date:  2003

6.  Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms?

Authors:  Maria Stelmachowska-Banaś; Piotr Zdunowski; Wojciech Zgliczyński
Journal:  Endokrynol Pol       Date:  2009 Jan-Feb       Impact factor: 1.582

7.  Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly.

Authors:  Catherine Beauregard; Uyen Truong; Jules Hardy; Omar Serri
Journal:  Clin Endocrinol (Oxf)       Date:  2003-01       Impact factor: 3.478

8.  Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed.

Authors:  Tirissa J Reid; Kalmon D Post; Jeffrey N Bruce; M Nabi Kanibir; Carlos M Reyes-Vidal; Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-16       Impact factor: 3.478

Review 9.  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

Authors:  David Robert Clemmons
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

10.  Mortality in acromegaly: a metaanalysis.

Authors:  O M Dekkers; N R Biermasz; A M Pereira; J A Romijn; J P Vandenbroucke
Journal:  J Clin Endocrinol Metab       Date:  2007-10-30       Impact factor: 5.958

View more
  36 in total

Review 1.  The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.

Authors:  Saptarshi Bhattacharya; Sanjay Kalra; Deep Dutta; Deepak Khandelwal; Rajiv Singla
Journal:  Eur Endocrinol       Date:  2019-10-18

2.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

Review 3.  Diabetes in Patients With Acromegaly.

Authors:  A M Hannon; C J Thompson; M Sherlock
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

4.  Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

Authors:  R Helseth; S M Carlsen; J Bollerslev; J Svartberg; M Øksnes; S Skeie; S L Fougner
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

5.  MTHFR C677T polymorphism, folate status and colon cancer risk in acromegalic patients.

Authors:  Maria Luisa Torre; Giuseppina T Russo; Marta Ragonese; Annalisa Giandalia; Ernesto De Menis; Giorgio Arnaldi; Angela Alibrandi; Carmelo Buda; Giovanni Romanello; Elisabetta L Romeo; Domenico Cucinotta; Francesco Trimarchi; Salvatore Cannavo
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 6.  Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.

Authors:  Susan L Samson
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

7.  Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up.

Authors:  F Guaraldi; D Gori; G Beccuti; N Prencipe; R Giordano; Y Mints; V S Di Giacomo; A Berton; M Lorente; V Gasco; E Ghigo; R Salvatori; S Grottoli
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

8.  Effects of growth hormone on hepatic insulin sensitivity and glucose effectiveness in healthy older adults.

Authors:  Lala Forrest; Caroline Sedmak; Shanaz Sikder; Shivraj Grewal; S Mitchell Harman; Marc R Blackman; Ranganath Muniyappa
Journal:  Endocrine       Date:  2019-01-07       Impact factor: 3.633

Review 9.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

10.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.